2.54 USD
-0.05 (-1.93%)
2.52 USD
-0.02 (-0.79%)
BDTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. While BDTX has a great health rating, its profitability is only average at the moment. BDTX has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BDTX was profitable.
In the past year BDTX had a positive cash flow from operations.
BDTX had negative earnings in each of the past 5 years.
In the past 5 years BDTX always reported negative operating cash flow.
1.2 Ratios
BDTX's Return On Assets of 13.62% is amongst the best of the industry. BDTX outperforms 94.52% of its industry peers.
The Return On Equity of BDTX (17.03%) is better than 94.90% of its industry peers.
BDTX has a Return On Invested Capital of 6.74%. This is amongst the best in the industry. BDTX outperforms 93.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| ROIC | 6.74% |
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDTX has a better Profit Margin (30.69%) than 95.84% of its industry peers.
With an excellent Operating Margin value of 17.33%, BDTX belongs to the best of the industry, outperforming 93.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.33% | ||
| PM (TTM) | 30.69% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDTX has more shares outstanding than it did 1 year ago.
BDTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.45, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
BDTX's Altman-Z score of 0.45 is fine compared to the rest of the industry. BDTX outperforms 61.25% of its industry peers.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 0.45 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 8.94 indicates that BDTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.94, BDTX is doing good in the industry, outperforming 78.26% of the companies in the same industry.
A Quick Ratio of 8.94 indicates that BDTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.94, BDTX is doing good in the industry, outperforming 78.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 127.07% over the past year.
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
BDTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y138.15%
EPS Next 2Y20.91%
EPS Next 3Y6.09%
EPS Next 5Y10.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BDTX is valuated cheaply with a Price/Earnings ratio of 7.06.
Based on the Price/Earnings ratio, BDTX is valued cheaply inside the industry as 98.30% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.26, BDTX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.06 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 99.43% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.76 | ||
| EV/EBITDA | -7.42 |
4.3 Compensation for Growth
BDTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y20.91%
EPS Next 3Y6.09%
5. Dividend
5.1 Amount
No dividends for BDTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.54
-0.05 (-1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.45%
Inst Owner Change-1.13%
Ins Owners0.6%
Ins Owner Change0.22%
Market Cap144.70M
Revenue(TTM)70.00M
Net Income(TTM)21.48M
Analysts86.67
Price Target9.44 (271.65%)
Short Float %10.85%
Short Ratio4.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.9%
Min EPS beat(2)24.48%
Max EPS beat(2)37.31%
EPS beat(4)4
Avg EPS beat(4)1123.98%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)572.61%
EPS beat(12)12
Avg EPS beat(12)384.24%
EPS beat(16)16
Avg EPS beat(16)291.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.78%
PT rev (3m)-5.61%
EPS NQ rev (1m)-6.86%
EPS NQ rev (3m)-2.15%
EPS NY rev (1m)36.69%
EPS NY rev (3m)52.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.06 | ||
| Fwd PE | N/A | ||
| P/S | 2.07 | ||
| P/FCF | 6.76 | ||
| P/OCF | 6.76 | ||
| P/B | 1.15 | ||
| P/tB | 1.15 | ||
| EV/EBITDA | -7.42 |
EPS(TTM)0.36
EY14.17%
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)0.38
FCFY14.79%
OCF(TTM)0.38
OCFY14.79%
SpS1.23
BVpS2.21
TBVpS2.21
PEG (NY)0.05
PEG (5Y)N/A
Graham Number4.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 143.37% | ||
| ROICexgc | 143.37% | ||
| OM | 17.33% | ||
| PM (TTM) | 30.69% | ||
| GM | N/A | ||
| FCFM | 30.57% |
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 171.61% | ||
| Profit Quality | 99.62% | ||
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 | ||
| Altman-Z | 0.45 |
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y138.15%
EPS Next 2Y20.91%
EPS Next 3Y6.09%
EPS Next 5Y10.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y114.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year120.25%
EBIT Next 3Y4.07%
EBIT Next 5Y-1.54%
FCF growth 1Y128.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.65%
OCF growth 3YN/A
OCF growth 5YN/A
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you provide the ChartMill fundamental rating for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a fundamental rating of 4 / 10 to BDTX.
Can you provide the valuation status for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a valuation rating of 5 / 10 to BLACK DIAMOND THERAPEUTICS I (BDTX). This can be considered as Fairly Valued.
Can you provide the profitability details for BLACK DIAMOND THERAPEUTICS I?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for BDTX stock?
The Price/Earnings (PE) ratio for BLACK DIAMOND THERAPEUTICS I (BDTX) is 7.06 and the Price/Book (PB) ratio is 1.15.
Can you provide the financial health for BDTX stock?
The financial health rating of BLACK DIAMOND THERAPEUTICS I (BDTX) is 7 / 10.